A detailed history of Mai Capital Management transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Mai Capital Management holds 658,794 shares of CRDF stock, worth $2.11 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
658,794
Previous 551,124 19.54%
Holding current value
$2.11 Million
Previous $2.94 Million 50.32%
% of portfolio
0.01%
Previous 0.03%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$2.22 - $5.89 $239,027 - $634,176
107,670 Added 19.54%
658,794 $1.46 Million
Q1 2024

May 08, 2024

BUY
$1.46 - $5.91 $250,848 - $1.02 Million
171,814 Added 45.3%
551,124 $2.94 Million
Q4 2023

Feb 09, 2024

BUY
$0.96 - $1.55 $148,378 - $239,569
154,561 Added 68.77%
379,310 $561,000
Q3 2023

Nov 14, 2023

BUY
$1.38 - $2.18 $310,153 - $489,952
224,749 New
224,749 $312,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $139M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Mai Capital Management Portfolio

Follow Mai Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Mai Capital Management with notifications on news.